Taking on KRAS G12C

More Science and Innovation Stories

KRAS Conversations

Learn More About KRAS G12C

Follow Amgen Oncology on Twitter and LinkedIn for the latest updates and learn more about Amgen's commitment to the relentless pursuit of breakthroughs for cancer patients with NSCLC and other solid tumors with KRAS G12C mutations at AmgenOncology.com.